New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
04:55 EDTLGND, LGND, LGND, MDCO, MDCO, MDCO, ESRX, ESRX, ESRX, NPSP, NPSP, NPSP, BDSI, BDSI, BDSI, FEIC, FEIC, FEIC, HUM, HUM, HUM, IDIX, IDIX, IDIX, SYK, SYK, SYK, STE, STE, STE, PRTA, PRTA, PRTABofA/Merrill to hold a conference
2014 Healthcare Conference to be held in Las Vegas on May 13-15.
News For LGND;STE;SYK;IDIX;HUM;FEIC;BDSI;NPSP;ESRX;MDCO;PRTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 20, 2014
06:06 EDTMDCOThe Medicines Co. upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
November 19, 2014
07:09 EDTBDSIJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
November 18, 2014
10:28 EDTLGNDLigand sees 2015 revenue $81M-$83M, consensus $91.87M
Three estimates make up consensus. Guidance issued in analyst day presentation slides.
10:27 EDTLGNDLigand sees 2017 EPS above $4.65, revenue above $146M
Subscribe for More Information
10:27 EDTLGNDLigand sees 2016 EPS above $3.20, revenue above $107M
Subscribe for More Information
10:25 EDTLGNDLigand guides 2015 EPS $2.14-$2.18, consensus $2.42
Subscribe for More Information
November 17, 2014
14:06 EDTHUMHumana to offer plans on 15 state ACA individual market exchanges in 2015
Subscribe for More Information
November 16, 2014
13:41 EDTMDCOThe Medicines Co. presents findings from MDCO-216 study
The Medicines Company presented findings from a new Phase 1 study showing that a single infusion of MDCO-216, an investigational lipid-modifying agent, in both healthy and CAD patients, modified key lipid parameters including ApoA-1, phospholipids, HDL, pre-beta 1 HDL and Apo E, markedly increased ABCA1 mediated efflux, a potential marker of reverse cholesterol transport and was well tolerated. The study was presented today as part of a poster session at The American Heart Association’s Annual Scientific Sessions in Chicago. Clinical findings have shown that human carriers of the ApoA-1 Milano variant have a reduced incidence of cardiovascular disease. MDCO-216, currently under development by The Medicines Company, is a complex of recombinant human Apo A1 with phospholipids to emulate an HDL particle. MDCO-216 has the potential to modify atherosclerotic disease by promoting reverse cholesterol transport, and its potential impact on reducing cardiovascular events in acute coronary syndrome, ACS, patients. “This study provides a signal that MDCO-216 is able to modulate lipid parameters consistent with those humans with the ApoA-1 variant, had an important effect on markers of reverse cholesterol transport such as pre-beta1 HDL and ABCA1 mediated efflux, and importantly was well-tolerated,” commented David Kallend, MBBS, Vice President and Global Medical Director for the Lipid Programs at The Medicine Company. “These findings support the continued development of MDCO-216 as a potential treatment to help address a currently unmet need in coronary artery disease patients."
November 14, 2014
17:21 EDTLGNDLigand to host analyst day
Analyst Day to be held in New York on November 18 at 10 am. Webcast Link
16:39 EDTESRXBerkshire Hathaway gives quarterly update on stakes
Subscribe for More Information
14:53 EDTESRXCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
10:33 EDTMDCOThe Medicines Co. to present new data on MDCO-216 at AHA sessions
Subscribe for More Information
November 12, 2014
09:16 EDTLGNDLigand reports GlaxoSmithKline EU regulatory submission for Revolade
Subscribe for More Information
08:58 EDTHUMManaged Care earnings risk low from King vs. Burwell, says Leerink
Leerink believes the Supreme Court decision to the King vs. Burwell case carries low earnings risk for Managed Care companies. The case to determine the legality of Exchange subsidies administered by the Federal Government carries less than 2% and 3% of earnings risk for 2014 and 2015 estimates, respectively, Leerink believes. The firm says Humana (HUM) and Cigna (CI) are currently losing money on Exchanges, and thus could benefit from any Federal Exchange membership loss. Leerink lists Aetna (AET), Centene (CNC), WellPoint (WLP) and Molina Healthcare (MOH) as being most impacted.
November 11, 2014
12:55 EDTHUMWorkarounds to likely protect insurers from Supreme Court decision, says Wedbush
Subscribe for More Information
November 10, 2014
16:08 EDTNPSPNPS Pharmaceuticals sees FY14 OpEx $185M-$195M vs. prior view of $180M-$200M
Subscribe for More Information
16:07 EDTNPSPNPS Pharmaceuticals sees FY14 revenue at low end of $100M-$110M range
Subscribe for More Information
16:06 EDTNPSPNPS Pharmaceuticals reports Q3 EPS (2c), consensus 2c
Subscribe for More Information
15:53 EDTPRTACredit Suisse to hold a conference
Healthcare Conference is being held in Scottsdale, Arizona on November 10-13 with webcasted company presentations to begin on November 11 at 10:30 am; not all company presentations may be webcasted. Webcast Link
15:26 EDTNPSPNotable companies reporting after market close
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use